Dulaglutide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dulaglutide: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Dulaglutide is a GLP-1 receptor agonist injection, originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for opsismodysplasia, a rare skeletal dysplasia, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 97.05% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, dulaglutide is a GLP-1 receptor agonist. It acts on incretin signalling and its efficacy in type 2 diabetes mellitus is established.
Opsismodysplasia is a rare skeletal dysplasia caused by INPPL1 (SHIP2) mutations, which affect PI3K/AKT signalling and endochondral ossification. No plausible mechanistic link to GLP-1 receptor agonism has been documented. The high TxGNN score (0.971) most likely reflects graph-topology artefacts, such as shared insulin/PI3K pathway neighbours in the knowledge graph, rather than a biological rationale.
The other top predictions show a similar pattern. Several (stiff person syndrome, focal stiff limb syndrome, thiamine-responsive dysfunction syndrome, pancreatic agenesis) appear to be driven by a shared diabetes phenotype. The lipodystrophy conditions appear to be driven by proximity to the metabolic disease cluster. Pancreatic agenesis is biologically implausible for dulaglutide, because the drug depends on functional beta cells. Autoimmune oophoritis scored much lower (69.6%), with weak support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14968P | TRULICITY INJECTION 0.75MG/0.5ML | Injection, solution | Not listed in the data compiled |
| SIN14967P | TRULICITY INJECTION 1.5MG/0.5ML | Injection, solution | Not listed in the data compiled |
Both licences are valid single-ingredient products from Eli Lilly and Company (Vetter Pharma-Fertigung as co-manufacturer).
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs, mostly of Moderate severity and a few Minor. The 20 listed in the data compiled include:
- Sympathomimetics and bronchodilators: phenylephrine, pseudoephedrine, epinephrine, formoterol, salbutamol
- Corticosteroids: hydrocortisone (Moderate), and topical hydrocortisone and alclometasone (Minor)
- Diuretics: furosemide, hydrochlorothiazide, acetazolamide
- Hormonal agents: ethinylestradiol, estradiol, norethisterone
- Others: ethanol, fosamprenavir, fosphenytoin, gemifloxacin, alpelisib, aripiprazole
Many of these may affect blood glucose control, so monitoring is warranted if co-administered.
For key warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (Evidence Level L5). No credible mechanism links GLP-1 receptor agonism to opsismodysplasia, and the high score likely reflects knowledge-graph artefacts. None of the other nine predicted indications has supporting evidence either.
To proceed, the following is needed:
- Mechanism of action data for dulaglutide
- Package insert warnings and contraindications from the HSA, for safety screening
- Preclinical or mechanistic evidence connecting GLP-1 receptor signalling to INPPL1/SHIP2-related skeletal pathology
- A literature and trial search for the predicted indication, and re-evaluation if any evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.